Skip to content

The role and clinical value of mtDNA in chronic obstructive pulmonary disease

The role and clinical value of mtDNA in chronic obstructive pulmonary disease

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039039
Enrollment
Unknown
Registered
2020-10-14
Start date
2020-11-01
Completion date
Unknown
Last updated
2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Control group (healthy people):No
Stable patients of COPD:No
Acute exacerbation of COPD:No

Sponsors

Chengdu Second People Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The research object of this subject comes from a total of 300 COPD patients and healthy people selected from 2020-2023 in outpatients and inpatients of our hospital. The diagnosis of COPD is based on the "Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Diseases" formulated by the Respiratory Medicine Branch of the Chinese Medical Association in 2011, referred to as the "Guidelines", combined with the corresponding medical history, risk factor exposure history, physical signs, and lung function after the application of bronchodilators Comprehensive analysis and diagnosis of indicators. According to the clinical severity classification standard provided by the , COPD patients are divided into grade I, grade II, grade III, and grade IV groups [After inhaling bronchodilators, the ratio of forced expiratory volume/forced vital capacity in 1 second ( FEV, /FVC) 80% is grade I; after inhalation of bronchodilator, FEV1/FVC Divide COPD patients into acute exacerbations and stable phases. According to relevant literature, non-smokers are defined as past or current smoking history = 20 packs/year.

Exclusion criteria

Exclusion criteria: 1.Smoking history greater than 1 pack/year but less than 20 packs/year; 2.BMI is greater than 40 kg/m2; 3.Patients with other lung diseases: such as asthma, interstitial lung disease, lung cancer, lung transplantation, lung resection, etc.; 4.Patients with other serious diseases: unstable angina, myocardial infarction, controlled heart failure, severe arrhythmia and other diseases in the past 6 weeks; 5.Currently using inhaled or intravenous corticosteroid drugs.

Design outcomes

Primary

MeasureTime frame
the copy amount of mtDNA;Lung function test;IL-8;TNF-a;NLRP3;IL-1ß;IL-18;RAGE;Nrf2;

Countries

China

Contacts

Public ContactHao Yan

Chengdu Second People Hospital

haoy6666@aliyun.com+86 13320995671

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026